GT Biopharma is trading 7.00% higher at $6.71 on October 15, 2026; no new company-specific announcement explaining the gain was identified.
- A resale registration for up to 13,502,835 shares was filed earlier and does not establish a cause for the move.
- Hotter-than-expected U.S. inflation intensified rate concerns and weighed on technology shares, but that broader-market backdrop does not explain GT Biopharma’s increase.